title: Chronic myeloid leukemia: reminiscences and dreams.
abstract: With the deaths of Janet Rowley and John Goldman in December 2013, the world lost two pioneers in the field of chronic myeloid leukemia. In 1973, Janet Rowley, unraveled the cytogenetic anatomy of the Philadelphia chromosome, which subsequently led to the identification of the BCR-ABL1 fusion gene and its principal pathogenetic role in the development of chronic myeloid leukemia. This work was also of major importance to support the idea that cytogenetic changes were drivers of leukemogenesis. John Goldman originally made seminal contributions to the use of autologous and allogeneic stem cell transplantation from the late 1970s onwards. Then, in collaboration with Brian Druker, he led efforts to develop ABL1 tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia in the late 1990s. He also led the global efforts to develop and harmonize methodology for molecular monitoring, and was an indefatigable organizer of international conferences. These conferences brought together clinicians and scientists, and accelerated the adoption of new therapies. The abundance of praise, tributes and testimonies expressed by many serve to illustrate the indelible impressions these two passionate and affable scholars made on so many people's lives. This tribute provides an outline of the remarkable story of chronic myeloid leukemia, and in writing it, it is clear that the historical triumph of biomedical science over this leukemia cannot be considered without appreciating the work of both Janet Rowley and John Goldman.
authors.affiliation: Tufts University Medical Center, Boston, MA, USA tmughal911@hotmail.com tmughal@tuftsmedicalcenter.org.
authors.forename: Tariq I
authors.initials: TI
authors.lastname: Mughal
authors.affiliation: Fredrick Hutchinson Cancer Center, University of Washington, Seattle, WA, USA.
authors.forename: Jerald P
authors.initials: JP
authors.lastname: Radich
authors.affiliation: University of Utah, Huntsman Cancer, Institute, Salt Lake City, UT, USA.
authors.forename: Michael W
authors.initials: MW
authors.lastname: Deininger
authors.affiliation: Imperial College London, Hammersmith Hospital, UK.
authors.forename: Jane F
authors.initials: JF
authors.lastname: Apperley
authors.affiliation: University of Adelaide, Australia.
authors.forename: Timothy P
authors.initials: TP
authors.lastname: Hughes
authors.affiliation: Newcastle University, Newcastle-upon-Tyne, UK.
authors.forename: Christine J
authors.initials: CJ
authors.lastname: Harrison
authors.affiliation: University of Milano-Bicocca, Monza, Italy.
authors.forename: Carlo
authors.initials: C
authors.lastname: Gambacorti-Passerini
authors.affiliation: University of Turin, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Saglio
authors.affiliation: MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Jorge
authors.initials: J
authors.lastname: Cortes
authors.affiliation: Boston Children's Hospital, Harvard Medicine, School, Boston, MA, USA.
authors.forename: George Q
authors.initials: GQ
authors.lastname: Daley
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D020732:Cytogenetic Analysis / Q000266:history / Q000379:methods; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics; D049673:History, 20th Century; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D058990:Molecular Targeted Therapy / Q000266:history / Q000379:methods; D009154:Mutation; D010677:Philadelphia Chromosome; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D012106:Research / Q000266:history
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D016044:Fusion Proteins, bcr-abl